Related references
Note: Only part of the references are listed.A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction
Si Chen et al.
CIRCULATION (2020)
Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction
Mei Methawasin et al.
CIRCULATION-HEART FAILURE (2020)
Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study
Di Zhao et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Paul W. Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease
Lutz Froelich et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
David A. Morrow et al.
EUROPEAN HEART JOURNAL (2019)
Distinct Phenotypes Induced by Three Degrees of Transverse Aortic Constriction in Mice
Daniel A. Richards et al.
SCIENTIFIC REPORTS (2019)
Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload
Nazari Polidovitch et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study
Robert J. Charnigo et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA
Wendy Ying et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway
Min Park et al.
BASIC RESEARCH IN CARDIOLOGY (2018)
Echocardiographic evaluation of diastolic function in mouse models of heart disease
Moritz Schnelle et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2018)
Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure
Reshma S. Baliga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease
Kristen M. Kokkonen-Simon et al.
JCI INSIGHT (2018)
C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling
Pan-xia Wang et al.
ACTA PHARMACOLOGICA SINICA (2017)
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
Zhanna Kobalava et al.
CARDIOVASCULAR THERAPEUTICS (2016)
PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction
Walter E. Knight et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate
Robrecht Thoonen et al.
CIRCULATION-HEART FAILURE (2015)
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
Dong I. Lee et al.
NATURE (2015)
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction A Randomized Clinical Trial
Margaret M. Redfield et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Ventriculo-arterial decoupling in acutely altered hemodynamic states
Fabio Guarracino et al.
CRITICAL CARE (2013)
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Jessie Gu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure:: A double-blind, placebo-controlled clinical trial
Alice Behling et al.
JOURNAL OF CARDIAC FAILURE (2008)
Long-term use of sildenafil in the therapeutic management of heart failure
Marco Guazzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Cardiac myosin binding protein C phosphorylation is cardioprotective
Sakthivel Sadayappan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
E Takimoto et al.
NATURE MEDICINE (2005)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
B Dahlöf et al.
LANCET (2002)
Prognostic implications of left ventricular hypertrophy
BA Vakili et al.
AMERICAN HEART JOURNAL (2001)
Share Paper
